Join our Q2 earnings call August 11th at 8:30am EDT Click here for webcast details

OUR FOCUS

Developing next generation peptide therapeutics for obesity and liver disease

OUR PROGRAMS

We are a clinical stage biopharmaceutical company developing peptide-based therapeutics:

  • Pemvidutide for obesity
  • Pemvidutide for non-alcoholic steatohepatitis (NASH)
  • HepTcell™ for chronic hepatitis B
VIEW PIPELINE